Elaine’s stories explore the boom in new obesity treatments, new drug payment models, the ways companies are affected by FDA changes, and the emerging psychedelics drug sector. She co-writes The ...

Genentech is continuing its summer of downsizing and cost-cutting, this time with plans to terminate a cell therapy deal worth as much as $2 billion. The pact is with Adaptive Biotechnologies and ...

Genentech will close its cancer immunology research department, and unit head and renowned cell biologist Ira Mellman, who has been with the company for 17 years, will depart in the coming months. The ...

SAN DIEGO, CA—Aviv Regev, PhD, head and executive vice president of Research and Early Development at Genentech, kicked off the Opening Plenary Session at the American Association for Cancer Research ...